Positron Diagnostics, the advanced PET/CT Imaging Center, begins operations in Nicosia, marking a new era in diagnostic medicine in Cyprus.
The Diagnostic Center features cutting-edge technology for accurate and reliable diagnoses. The new PET/CT service is expected to significantly improve both access to imaging and quality of care, with particular benefits for patients with solid tumors and hematological malignancies.
The state-of-the-art GE HealthCare Discovery IQ Gen 2 PET/CT scanner, combined with a fully diagnostic CT, offers ultra-fast scan times, high-resolution images, and reduced radiation dose for patients. Additionally, the machine's bore diameter is larger than older PET/CT technology, making it ideal for individuals who suffer from claustrophobia. The radiopharmaceuticals used in routine PET/CT examinations are produced within the Center, which has a modern cyclotron and fully equipped radiochemistry laboratories.
PET is a non-invasive diagnostic method that uses small amounts of radioactive material to diagnose a wide range of diseases, such as cancer and, to a lesser but continually increasing degree, to investigate inflammation, cardiovascular diseases, and neurological disorders.
It can detect biochemical changes in tissues before morphological lesions from the disease appear. This information serves as prognostic tools for clinicians for targeted monitoring and more personalized patient care, and helps researchers develop early biomarkers that facilitate diagnosis and promote drug development.
It should be noted that the radiopharmaceuticals used in PET/CT examinations are not related to the contrast agents administered in conventional imaging examinations and therefore do not cause allergic reactions.
Patients with renal dysfunction or insufficiency can undergo PET/CT examination without any renal burden, while there is no impact on patients with thyroid gland disorders as the radiopharmaceuticals do not contain iodine.
Positron Diagnostics declares its commitment to transforming healthcare in the community. With the installation of this state-of-the-art PET/CT scanner in Cyprus, our goal is to enhance oncological care and achieve better outcomes for all patients.
Patients will benefit not only from increased local access to PET/CT diagnostic services, but also from minimal waiting times for appointments and faster diagnostic results, enabling treating physicians to design optimal healthcare treatment plans.
For more information or to book an appointment, contact us at info@positron.health or call +357 22053555.
The Diagnostic Center features cutting-edge technology for accurate and reliable diagnoses. The new PET/CT service is expected to significantly improve both access to imaging and quality of care, with particular benefits for patients with solid tumors and hematological malignancies.
The state-of-the-art GE HealthCare Discovery IQ Gen 2 PET/CT scanner, combined with a fully diagnostic CT, offers ultra-fast scan times, high-resolution images, and reduced radiation dose for patients. Additionally, the machine's bore diameter is larger than older PET/CT technology, making it ideal for individuals who suffer from claustrophobia. The radiopharmaceuticals used in routine PET/CT examinations are produced within the Center, which has a modern cyclotron and fully equipped radiochemistry laboratories.
PET is a non-invasive diagnostic method that uses small amounts of radioactive material to diagnose a wide range of diseases, such as cancer and, to a lesser but continually increasing degree, to investigate inflammation, cardiovascular diseases, and neurological disorders.
It can detect biochemical changes in tissues before morphological lesions from the disease appear. This information serves as prognostic tools for clinicians for targeted monitoring and more personalized patient care, and helps researchers develop early biomarkers that facilitate diagnosis and promote drug development.
It should be noted that the radiopharmaceuticals used in PET/CT examinations are not related to the contrast agents administered in conventional imaging examinations and therefore do not cause allergic reactions.
Patients with renal dysfunction or insufficiency can undergo PET/CT examination without any renal burden, while there is no impact on patients with thyroid gland disorders as the radiopharmaceuticals do not contain iodine.
Positron Diagnostics declares its commitment to transforming healthcare in the community. With the installation of this state-of-the-art PET/CT scanner in Cyprus, our goal is to enhance oncological care and achieve better outcomes for all patients.
Patients will benefit not only from increased local access to PET/CT diagnostic services, but also from minimal waiting times for appointments and faster diagnostic results, enabling treating physicians to design optimal healthcare treatment plans.
For more information or to book an appointment, contact us at info@positron.health or call +357 22053555.